Smith & Nephew

SNN

시가총액 US$122억

SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.

Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El implante CARTIHEAL ocupará un lugar destacado en el Congreso de la Sociedad International de Regeneración de Cartílago & Preservación Articular (ICRS), que se celebrará en Oporto (Portugal) del 8 al 10 de octubre.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will take center stage at this week's International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit in Porto, Portugal from October 8-10.

Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata all'International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, che si terrà a Porto, in Portogallo, dall'8 al 10 ottobre.

SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.

The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted choice for trauma surgeons worldwide due to its breadth of implant offerings, procedural efficiency and clinically relevant innovation.1-5  EVOS PELVIC System helps surgeons address a broad range of fracture patterns and disruptions in highly complex procedures.

The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted choice for trauma surgeons worldwide due to its breadth of implant offerings, procedural efficiency and clinically relevant innovation.1-5  EVOS PELVIC System helps surgeons address a broad range of fracture patterns and disruptions in highly complex procedures.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit the Smith+Nephew booth during ICSES to learn more about the following technologies: TENDON SEAM Rotator Cuff Repair System Recently acquired by Smith+Nephew, the TENDON SEAM System is a unique rotator cuff repair solution that offers superior load sharing designed to maximize repair strength throughout the healing period.1-4,*,** The construct features multiple tightly spaced 2x10mm anchors connected by a continuous stitch designed to distribute forces across the repaired tendon with a seam of fixation perpendicular to the direction of load.

Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the results of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). The Tender Offer was made upon and is subject to the terms and conditions set forth in the Offer to Purchase.

Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the pricing of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). The Tender Offer is made upon and is subject to the terms and conditions set forth in the Offer to Purchase.